Investor Relations

Ascendis Pharma is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.

Stock Information
ASND (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.64 (2.46%)
Data as of 05/23/17 3:59 p.m. ET
Refresh quote
Stock chart for: ASND.O.  Currently trading at $25.41 with a 52 week high of $31.86 and a 52 week low of $11.92.
Recent NewsMore >>
Ascendis Pharma A/S Reports First Quarter 2017 Financial Results
Ascendis Pharma A/S Announces First Quarter 2017 Financial Results Conference Call on May 23
Ascendis Pharma A/S Announces Upcoming Investor Presentations
Upcoming EventsMore >>
Q1 2017 Ascendis Pharma Earnings Conference Call
Tuesday, May 23, 2017 4:30 p.m. ET
Primary IR Contact
Scott T. Smith
Chief Financial Officer
Ascendis Pharma

Data provided by Nasdaq. Minimum 15 minutes delayed.